Vericel
VCEL
40.74
+0.69
+1.72%
Vericel
US · VCEL
#2759 by market cap
Listed 1970
40.74
+0.69
+1.72%
Live - 5344 symbols - heartbeat 446s ago
· 2026-10-08 04:26
Pre-market
40.69
-0.12%
After-hours
40.74
0.00%
- Market cap
- 2.09B
- P/E (TTM)i
- 84.88
- P/Bi
- 5.64
- EPSi
- 0.32
- Div yieldi
- 0.00%
- 52W posi
- 58%
Reader sentiment
Are you bullish or bearish on VCEL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 9.44, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +16.45% YoY
Margins
- Gross margin
- 74.42%
- Operating margin
- 4.00%
- Net margin
- 5.98%
Key ratios & quality
- Altman Z-Scorei
- 9.44
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 90.86M | 117.85M | 124.18M | 156.18M | 164.37M | 197.52M | 237.22M | 276.26M |
| Gross profit | 58.70M | 80.28M | 84.23M | 106.03M | 109.79M | 135.58M | 172.11M | 205.60M |
| Selling & admin expenses | 49.01M | 61.14M | 68.84M | 97.59M | 106.90M | 121.00M | 142.79M | 166.99M |
| Research & development | 13.60M | 30.39M | 13.02M | 16.29M | 19.94M | 21.04M | 24.80M | 27.56M |
| Operating profit | -3.91M | -11.25M | 2.37M | -7.85M | -17.06M | -6.46M | 4.52M | 11.04M |
| Pretax profit | -8.14M | -9.67M | 3.04M | -7.58M | -15.99M | -2.37M | 10.51M | 17.38M |
| Tax | 0 | 0 | 180.00K | -111.00K | 721.00K | 814.00K | 148.00K | 859.00K |
| Net profit | -8.14M | -9.67M | 2.86M | -7.47M | -16.71M | -3.18M | 10.36M | 16.52M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.20 | -0.22 | 0.06 | -0.16 | -0.35 | -0.07 | 0.20 | 0.32 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 52.60M | 63.24M | 67.50M | 92.92M | 68.43M | 77.46M |
| Gross profit | 36.27M | 46.61M | 49.59M | 73.13M | 49.27M | 56.40M |
| Selling & admin expenses | 41.80M | 41.91M | 39.82M | 43.46M | 49.23M | 48.48M |
| Research & development | 7.26M | 6.73M | 6.32M | 7.25M | 8.10M | 7.49M |
| Operating profit | -12.79M | -2.03M | 3.45M | 22.42M | -8.06M | 434.00K |
| Pretax profit | -11.25M | -553.00K | 5.07M | 24.10M | -6.30M | 2.21M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -11.25M | -553.00K | 5.07M | 23.24M | -6.30M | 2.21M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.23 | -0.01 | 0.10 | 0.45 | -0.12 | 0.04 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 112.78M | 111.66M | 123.56M | 158.46M | 186.87M | 205.63M | 212.78M | 247.44M |
| Cash & ST investments | 82.92M | 69.72M | 75.81M | 103.40M | 119.54M | 109.56M | 116.21M | 137.50M |
| Inventory | 3.56M | 6.82M | 9.36M | 13.38M | 15.99M | 13.09M | 17.37M | 17.56M |
| Total assets | 118.69M | 153.24M | 205.61M | 243.71M | 273.00M | 353.66M | 432.72M | 487.97M |
| Total current liabilities | 14.79M | 19.80M | 22.48M | 26.05M | 37.46M | 45.75M | 50.29M | 49.15M |
| Short-term debt | -- | 5.50M | 4.44M | 2.99M | 4.30M | 6.19M | 9.37M | 14.09M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 16,458,000.00 | 42,147,000.00 | 71,348,000.00 | 73,243,000.00 | 80,731,000.00 | 127,705,000.00 | 140,755,000.00 | 133,329,000.00 |
| Total equity | 102.23M | 111.09M | 134.26M | 170.46M | 192.27M | 225.95M | 291.97M | 354.64M |
| Retained earnings | -369.01M | -378.68M | -375.82M | -383.29M | -400.00M | -403.18M | -392.82M | -376.30M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 197.64M | 204.58M | 221.97M | 247.44M | 244.06M | 264.73M |
| Cash & ST investments | 112.90M | 116.88M | 135.38M | 137.50M | 145.34M | 162.46M |
| Inventory | 17.11M | 16.83M | 18.16M | 17.56M | 18.35M | 18.38M |
| Total assets | 424.59M | 435.61M | 453.27M | 487.97M | 485.63M | 502.87M |
| Total current liabilities | 39.45M | 41.13M | 45.58M | 49.15M | 47.16M | 52.53M |
| Short-term debt | 11.16M | 13.75M | 13.85M | 14.09M | 14.18M | 14.27M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 129,100,000.00 | 128,799,000.00 | 131,416,000.00 | 133,329,000.00 | 129,396,000.00 | 132,825,000.00 |
| Total equity | 295.49M | 306.81M | 321.86M | 354.64M | 356.23M | 370.04M |
| Retained earnings | -404.06M | -404.61M | -399.54M | -376.30M | -382.60M | -380.39M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -412.00K | -7.18M | 17.57M | 29.04M | 17.69M | 35.31M | 58.16M | 51.91M |
| Depreciation & amortization | 1.43M | 1.74M | 2.38M | 2.97M | 3.98M | 4.63M | 5.50M | 11.54M |
| Free cash flow | -3.09M | -9.80M | 14.95M | 21.13M | 10.09M | 7.80M | -5.81M | 24.75M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 70.03M | 5.29M | 6.63M | 11.18M | 3.65M | 6.00M | 24.52M | 13.93M |
| Ending cash balance | 18.29M | 26.98M | 33.83M | 68.54M | 51.07M | 86.87M | 85.05M | 100.09M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 6.60M | 8.21M | 22.08M | 15.01M | 16.38M | 16.19M |
| Depreciation & amortization | 2.69M | 2.83M | 2.94M | 3.09M | 3.27M | 3.62M |
| Free cash flow | -7.61M | 81.00K | 19.45M | 12.83M | 15.13M | 14.26M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 9.41M | 1.79M | 1.48M | 1.26M | 1.56M | 2.86M |
| Ending cash balance | 79.71M | 80.53M | 100.40M | 100.09M | 109.30M | 125.36M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -13.04 | -9.06 | 2.33 | -4.90 | -9.21 | -1.52 | 4.00 | 5.11 |
| ROA %i | -9.39 | -7.11 | 1.60 | -3.33 | -6.47 | -1.02 | 2.64 | 3.59 |
| ROIC %i | -11.70 | -8.38 | 1.36 | -3.77 | -7.59 | -2.30 | 1.32 | 2.48 |
| 5-year avg ROE %i | -- | -- | -- | -82.98 | -6.78 | -4.47 | -1.86 | -1.31 |
| EBIT margin %i | -7.05 | -8.19 | 2.46 | -4.85 | -9.50 | -0.90 | 4.69 | 6.52 |
| FCF / sales %i | -- | -- | 12.04 | 13.53 | 6.14 | 3.95 | -- | 8.96 |
| Current ratioi | 7.62 | 5.64 | 5.50 | 6.08 | 4.99 | 4.49 | 4.23 | 5.03 |
| Quick ratioi | 7.19 | 5.15 | 4.91 | 5.41 | 4.43 | 3.67 | 3.53 | 4.52 |
| Debt / assetsi | 0.00 | 18.18 | 25.92 | 20.59 | 17.42 | 24.90 | 22.87 | 19.75 |
| LT debt / equityi | -- | 20.12 | 36.40 | 27.68 | 22.50 | 36.23 | 30.69 | 23.20 |
| Interest coveragei | -3.70 | -1,207.13 | 508.33 | -1,894.50 | -42.68 | -2.95 | 18.12 | 28.58 |
| Revenue CAGR (3Y) %i | 21.09 | 29.41 | 24.78 | 19.79 | 11.73 | 16.73 | 14.95 | 18.90 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -19.50 | -- | 34.86 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 1.13 | 2.59 | 4.52 | 5.11 | 6.59 | 7.16 |
| ROA %i | 0.76 | 1.75 | 3.10 | 3.59 | 4.72 | 5.16 |
| ROIC %i | -0.42 | 0.67 | 2.14 | 2.48 | 4.15 | 4.63 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 1.57 | 3.16 | 5.35 | 6.52 | 7.86 | 8.40 |
| FCF / sales %i | -- | -- | 7.88 | 8.96 | 16.26 | 20.13 |
| Current ratioi | 5.01 | 4.97 | 4.87 | 5.03 | 5.18 | 5.04 |
| Quick ratioi | 4.20 | 4.40 | 4.30 | 4.52 | 4.62 | 4.53 |
| Debt / assetsi | 23.31 | 22.90 | 21.62 | 19.75 | 19.47 | 18.43 |
| LT debt / equityi | 29.72 | 28.03 | 26.15 | 23.20 | 22.56 | 21.18 |
| Interest coveragei | 6.09 | 12.74 | 22.27 | 28.58 | 36.04 | 40.19 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- MACI implants, kits, and instruments is the largest reported line at 84.57% of revenue, across 3 reported segments.
- The next-largest line, Epicel, is a distant second at 13.43% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
MACI implants, kits, and instruments84.57%
Epicel13.43%
NexoBrid2.00%
Quote time 2026-10-08 04:26:33 · For reference only, not investment advice and not tailored to your situation.